Are Puberty Blockers Reversible? A Sourced Guide for Families

TransHealthHub

Aug 22

5 min read

KEY TAKEAWAYS ON PUBERTY BLOCKERS:

Puberty blockers pause the physical changes of puberty. For most adolescents, puberty resumes once the medication stops, according to the Mayo Clinic and the American Academy of Pediatrics.
Puberty resuming is the best-established part of the reversibility picture. Less certain is how completely some effects, particularly bone density, catch back up over time.
A 2020 study in the Journal of Clinical Endocrinology and Metabolism found bone density measures normalized in transgender boys within a few years of adding hormone therapy, but stayed lower than average in transgender girls at the same point.
The American Medical Association, American Academy of Pediatrics, American Psychological Association, and Endocrine Society regard this medication, used appropriately, as safe and medically necessary for eligible adolescents.
The Cass Review and a 2025 U.S. Department of Health and Human Services report rated parts of the pediatric evidence base as low certainty. A low-certainty rating means more research is needed, not that harm has been demonstrated.

The short answer

Puberty blockers pause physical puberty, and for most adolescents, puberty resumes on its own once the medication is stopped. That reversal of the medication's core effect is the best-supported part of the reversibility question. What researchers are still working out is how completely some longer-term effects, particularly on bone density, catch up after treatment ends, and how confident the current evidence can be about that timeline. At TransHealthHub, we think families deserve both halves of that answer, not just the reassuring half.

What puberty-pausing medication actually does

You may see this medication called puberty blockers, puberty-pausing medication, or GnRH agonists; this page uses “puberty-pausing medication” for clarity, since the terms describe the same treatment. The medication works by pausing the hormone signals that drive puberty, rather than altering the body directly. According to the American Academy of Pediatrics, this class of medication has been used to delay puberty since the 1980s for children with central precocious puberty, a condition where puberty starts unusually early, and the same reversible mechanism is used for adolescents with gender dysphoria to pause the development of secondary sex characteristics.

Because the medication pauses a process rather than changing it permanently, the expectation built into how it works is that stopping it lets that paused process continue.

What happens when a young person stops taking it

The Mayo Clinic states plainly that GnRH analogues “don't cause permanent physical changes” and instead “pause puberty.” Its patient guidance, last reviewed in January 2026, adds that “when a person stops taking GnRH analogues, puberty starts again.” In practice, that means the physical changes that had been paused, such as breast or facial hair development, typically resume on the timeline the young person's body would have followed anyway.

That same guidance is direct about what still needs monitoring: possible long-term effects on bone density and growth, and effects on fertility that can depend on when the medication was started. The Mayo Clinic recommends yearly bone density testing and calcium and vitamin D support during treatment, which is a routine precaution rather than a sign of expected harm.

What's well established, and what's still being studied

Effect	What's well established	What's still being studied
Pubertal development	Resumes once the medication stops	How closely the resumed timeline matches what would have happened without treatment
Bone density	Density measures typically stabilize during treatment and increase after hormone therapy begins	How fully density catches up long term, especially in transgender girls
Fertility	Can be affected depending on the age treatment starts and how long it continues	Individualized counseling and, where relevant, fertility preservation options before starting
Height and growth	Growth resumes after the medication is stopped	Long-term growth outcomes across larger, longer studies

The bone density row reflects a real, sourced nuance rather than a simple yes or no. A 2020 study in the Journal of Clinical Endocrinology and Metabolism followed transgender adolescents through puberty-pausing treatment and into subsequent hormone therapy. Bone density measures stabilized or dipped slightly during the puberty-pausing phase, then increased significantly once hormone therapy began. At the three-year mark, those measures had returned to typical ranges in transgender boys, but remained lower than average in transgender girls.

The study's authors describe this as an open question for future research, not a settled outcome either way.

Families can read more about what typically follows puberty-pausing medication on our page about hormone therapy for trans youth, and about the diagnosis that often precedes this conversation on our gender dysphoria page.

Why the certainty of the evidence is still debated

Puberty-pausing medication is one of the more closely reviewed treatments in adolescent gender care, and it is worth naming who has reviewed it and what they actually found. The Cass Review, a UK government-commissioned review, and a 2025 U.S. Department of Health and Human Services report both rated the certainty of parts of the pediatric evidence base as low. As KFF's neutral summary of the HHS report puts it, the underlying research shows “the quality of evidence on the effects of any intervention is low, and evidence on harms is sparse.”

A low-certainty rating is a statement about how much high-quality, long-term research exists, not a finding that puberty-pausing medication causes harm. The American Medical Association, American Academy of Pediatrics, American Psychological Association, and Endocrine Society continue to regard this medication, when prescribed and monitored appropriately, as safe and medically necessary for eligible adolescents. Families weighing this treatment for a young person are best served by holding both facts at once: real questions remain open in the research, and the country's major medical and mental health associations still consider the treatment appropriate care within an individualized process involving a qualified clinician. Our overview of supportive care covers how that individualized process typically works.

Frequently asked questions

Are puberty blockers reversible? The medication's core effect, pausing puberty, is reversible: puberty generally resumes once treatment stops. Some longer-term effects, especially on bone density, take longer to fully assess and are still being studied.

What happens to bone density after stopping puberty-pausing medication? Research shows bone density measures typically stabilize during treatment and improve after hormone therapy begins, though full recovery appears to take longer in transgender girls than in transgender boys in the available data.

Can puberty-pausing medication affect fertility? It can, depending on when treatment starts and how long it continues, which is why clinicians typically discuss fertility counseling and preservation options with families before starting.